Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey.

@article{Finberg1998IncreasedSD,
  title={Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey.},
  author={John P.M. Finberg and J. Wang and K. S. Bankiewicz and Judith Harvey‐White and Irwin J. Kopin and David S. Goldstein},
  journal={Journal of neural transmission. Supplementum},
  year={1998},
  volume={52},
  pages={
          279-85
        }
}
Striatal extracellular fluid concentrations of dopamine and metabolites in response to direct striatal administration of two L-DOPA boluses administered sequentially were determined in three rhesus monkeys during halothane anesthesia. Whereas in an initial microdialysis run, generation of dopamine was less following the second L-DOPA bolus than the first, in a subsequent run, in which the selective MAO-B inhibitor R(+)-N-propargyl-1-aminoindan (rasagiline) was administered systemically (0.2 mg… 

Multisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brain.

TLDR
The present Review emphasizes the functional impact of extrastriatal release of dopamine induced by L-DOPA in both the therapeutic and side effects of L- DOPA.

Modification of L-DOPA pharmacological activity by MAO inhibitors

TLDR
There was no change in striatal MAO-A activity when 95% of dopaminergic innervation was reduced by 6-hydroxydopamine, as assessed by apomorphine-induced turning activity.

Striatal Dopamine Metabolism in Monoamine Oxidase B‐Deficient Mice : A Brain Dialysis Study

TLDR
It is suggested that in mice, DA is only metabolized byMAO A under basal conditions and by both MAO A and B at high concentrations, in contrast to the rat, where DA is always metabolizing by MAO B regardless of concentration.

The Design and Evaluation of an l-Dopa–Lazabemide Prodrug for the Treatment of Parkinson’s Disease

l-Dopa, the metabolic precursor of dopamine, is the treatment of choice for the symptomatic relief of the advanced stages of Parkinson’s disease. The oral bioavailability of l-dopa, however, is only

Past , present and future of A 2 A adenosine receptor antagonists in the therapy of Parkinson ’ s disease

TLDR
One further issue must be considered in order to develop fully optimized anti-parkinsonian drug therapy, namely the existence of receptor (hetero)dimers/oligomers of G protein-coupled.
...

References

SHOWING 1-10 OF 13 REFERENCES

Effect of selective and reversible MAO inhibitors on dopamine outflow in rat striatum: a microdialysis study.

TLDR
Reversible MAO-A inhibitors markedly increased the output of DA and concomitantly decreased theoutput of DOPAC and HVA, and these effects were absent with the highly selectiveMAO-B inhibitor Ro 19-6327.

Influence of Selective Inhibition of Monoamine Oxidase A or B on Striatal Metabolism of l‐DOPA in Hemiparkinsonian Rats

TLDR
A major role for MAO‐A in DA metabolism both intra‐ and extraneuronally in the rat striatum is indicated and is consistent with previous work on monoamine oxidase subtypes A and B.

l‐3,4‐Dihydroxyphenylalanine‐Induced Dopamine Release in the Striatum of Intact and 6‐Hydroxydopamine‐Treated Rats: Differential Effects of Monoamine Oxidase A and B Inhibitors

TLDR
A model in which exogenous l‐DOPA elicits enhanced extracellular accumulation of dopamine in the dopamine‐depleted striatum is supported because some transmitter synthesis occurs at nondopaminergic sites and the dopamine terminals that normally take up and catabolize this pool of transmitter are absent.

Monoamine Oxidase Activity and Monoamine Metabolism in Brains of Parkinsonian Patients Treated with l‐Deprenyl

TLDR
The data indicate that the therapeutic actions of l‐deprenyl may lie in its selective inhibition of MAO‐B resulting in increased brain levels of DA formed from L‐dihydroxyphenylacetic acid (L‐DOPA).

Distinct monoamine oxidase A and B populations in primate brain.

TLDR
These data illustrate the physiological independence of MAO A and B and show that neurons may be specialized for their degradative as well as their synthetic functions.

TYRAMINE ANTAGONISTIC PROPERTIES OF AGN 1135, AN IRREVERSIBLE INHIBITOR OF MONOAMINE OXIDASE TYPE B

TLDR
AGN 1135 possesses tyramine antagonistic activity which is qualitatively similar to that of (−)‐deprenyl but which cannot satisfactorily be explained by inhibition of neuronal or granular amine uptake.

SELECTIVE ACETYLENIC ‘SUICIDE’ AND REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE TYPES A AND B

TLDR
The present study has indicated that since the acetylenic compounds resemble the enzyme substrates the distance between the aromatic ring and the N‐propargyl terminal is crucial in designating the type A or type B MAO inhibitory property.

Monoamine oxidases: from brain maps to physiology and transgenics to pathophysiology.

TLDR
Recent advances in mapping the cellular sites of synthesis and catalytic activity, as well as age- and disease-related changes of monoamine oxidases A and B in the brain are reviewed.